Evidence-based guideline: Treatment of tardive syndromes Report of the Guideline Development Subcommittee of the American Academy of Neurology
VladimirLerner, Director of psychiatric ward, Ben Gurion University of the Negev, Be'er Sheva, Israellernervld@yahoo.com
Chanoch Miodownik, Vladimir Lerner, Be'er Sheva, Israel
Submitted August 21, 2013
We read the article by Bhidayasiri et al. with great interest. [1] Unfortunately, we found some inaccuracies. The authors cited only one of our articles regarding treatment of tardive dyskinesia (TD). [2] Even though the authors performed a search from 1966 -2011, they did not include two studies published in 2007 that could broaden the knowledge about new options of TD management. [3, 4] The first deals with vitamin B6 and the other with piracetam. Both studies include greater samples (50 and 40 subjects, respectively) and could be considered Class 1 evidence according to the authors' classification. Inclusion of this information could positively influence the weight and emphasize the significance of these medications. Our experience shows that different types of TD react uniquely to different types of medications.
1. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL,
Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes:
Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology;81:463-469.
2. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of
tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Am J Psychiatry 2001;158:1511-1514.
3. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for
tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68:1648-1654.
4. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of
piracetam in the treatment of tardive dyskinesia in schizophrenic
patients: a randomized, double-blind, placebo-controlled crossover study.
J Clin Psychiatry 2007;68:1031-1037.
For disclosures, contact the editorial office at journal@neurology.org
We read the article by Bhidayasiri et al. with great interest. [1] Unfortunately, we found some inaccuracies. The authors cited only one of our articles regarding treatment of tardive dyskinesia (TD). [2] Even though the authors performed a search from 1966 -2011, they did not include two studies published in 2007 that could broaden the knowledge about new options of TD management. [3, 4] The first deals with vitamin B6 and the other with piracetam. Both studies include greater samples (50 and 40 subjects, respectively) and could be considered Class 1 evidence according to the authors' classification. Inclusion of this information could positively influence the weight and emphasize the significance of these medications. Our experience shows that different types of TD react uniquely to different types of medications.
1. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology;81:463-469.
2. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-1514.
3. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68:1648-1654.
4. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68:1031-1037.
For disclosures, contact the editorial office at journal@neurology.org